002262 恩华药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)9.54717.20217.08817.64318.824
总资产报酬率 ROA (%)8.40215.01814.79215.27516.287
投入资产回报率 ROIC (%)9.21016.69616.59817.17318.498

边际利润分析
销售毛利率 (%)72.49972.82976.26077.20075.542
营业利润率 (%)26.50923.45223.34423.52525.470
息税前利润/营业总收入 (%)25.77322.79822.54623.00324.588
净利润/营业总收入 (%)22.67420.51520.47420.27721.632

收益指标分析
经营活动净收益/利润总额(%)101.15496.64994.92898.28597.462
价值变动净收益/利润总额(%)2.8924.3683.6643.9562.527
营业外收支净额/利润总额(%)-1.604-1.172-1.370-1.102-0.665

偿债能力分析
流动比率 (X)6.6256.4555.8575.9295.774
速动比率 (X)5.9555.6834.9555.0435.019
资产负债率 (%)12.14512.52813.84713.9270.135
带息债务/全部投入资本 (%)2.4251.6490.8500.9380.493
股东权益/带息债务 (%)3,965.7625,869.33511,456.12810,330.36719,840.843
股东权益/负债合计 (%)726.254700.820626.404620.161641.270
利息保障倍数 (X)-81.082-59.674-46.628-86.642-34.455

营运能力分析
应收账款周转天数 (天)75.20866.25162.70757.73661.037
存货周转天数 (天)140.185176.733232.955208.257170.637